Phoenix

Topas Therapeutics is focused on developing Topas particle conjugates (TPCs), an antigen coupled nanoparticle platform technology, that target liver sinusoidal endothelial cells to prompt anti-inflammatory immune responses and drive T cells towards tolerance. Topas wants to address areas of major unmet need, including autoimmune diseases.

Within PHOENIX, Topas Therapeutics is participating with innovative TPCs to re-instate immunological tolerance in a selected autoimmune disorder, in which antigen-specific therapies are still lacking. Disease-relevant peptides, which are triggering T lymphocyte-mediated autoimmune responses in this disease, are coupled to these TPCs and their efficacy will be assessed in preclinical proof of concept and toxicology studies using appropriate animal models, to disprove any toxic effects. The production of these particle-peptide conjugates will be ready to meet GMP requirements to be ready for later clinical application.

Watch our interview with TOPAS Therapeutics’ Chief Operating Officer Christian Schröter, PhD, to hear about the process of working with the PHOENIX-OITB consortium to access an array of services, guided by the PHOENIX SEP (single-entry-point).